Cevimeline (trade name Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

The global Cevimeline market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Cevimeline volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Cevimeline market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Cevimeline Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
20mg
30mg

Segment by Application
Hospital
Drug Store

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Daiichi Sankyo
Novel Laboratories
Rising Pharmaceuticals
West-Ward Pharmaceuticals
Lupin
Sun Pharmaceutical